Lorazepam

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
Thursday, March 7, 2024

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
Thursday, March 7, 2024

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Recognizing when someone is having a seizure – and how you can help during those first critical moments

Retrieved on: 
Wednesday, February 14, 2024

But experiencing a seizure does not always mean a person has epilepsy.

Key Points: 
  • But experiencing a seizure does not always mean a person has epilepsy.
  • Seizures can be provoked by acute head injuries, alcohol withdrawal and high blood sugar, among other things.

What does a seizure look like?

  • For some people, their seizure is a purely internal sensation.
  • In fact, most people with epilepsy have only relatively subtle, nonconvulsive seizures at first, then develop convulsive seizures over time.
  • This is the type of seizure most of us are familiar with, probably because it’s the kind most frequently depicted, though not always accurately, in movies and on television.
  • The most common type of epileptic seizure are those that are focal – that is, they arise from a confined region of the brain.

What causes a seizure to occur?


Seizures are the result of abnormal electrical activity in the brain. The bursts of activity disrupt normal functioning and initiate hyperactivity in the affected brain area, which then can affect the corresponding body part. For instance, if the seizure arises from the part of the brain involved in arm movement, that arm will experience involuntary hyperactivity.

If you’re a bystander, how can you help?

  • Many seizure-related injuries occur due to falling or coming in contact with sharp or hard objects.
  • If they begin to fall, help them to the floor as gently as possible and put something soft under their head.
  • During the convulsive phase of a seizure, breathing may be intermittent.
  • So turn the person on their side so they can breathe more easily and lower the risk of aspiration.
  • Following the seizure, and as the person gradually recovers and wakes up, help them sit up in a safe space.

Are new treatments available?

  • People with epilepsy, particularly those who experience frequent seizures, will often have emergency medications in their possession.
  • The most common emergency medications – also called seizure rescue medications – are a type of anticonvulsants called benzodiazepines.
  • Patients and their caretakers may have access to rescue medications and know how to use them.

What if it’s not a seizure?


If a bystander does not witness a seizure, but instead finds someone unresponsive or minimally responsive, call 911. They may be suffering from other medical issues, such as a drug overdose. And if you are interested in training and certification for seizure first aid, or if you simply want to know more, the Epilepsy Foundation has more information.

  • Jacob Pellinen has received research support from the Department of Neurology at the University of Colorado School of Medicine, the Colorado Clinical and Translational Sciences Institute, NIH/NINDS, and the American Epilepsy Society.
  • J. Pellinen serves as chair of the professional advisory board for the Epilepsy Foundation of Colorado and Wyoming (unpaid), serves as the Epilepsy Section Editor for Current Neurology and Neuroscience Reports, and has received compensation for serving on the scientific advisory board for SK Life Science.

Clinical Research Shows the Active Ingredient in Mikra’s Serenity Matches a Benzodiazepine in Effectiveness at Fighting Anxiety, Without Being Habit-Forming

Retrieved on: 
Wednesday, December 6, 2023

TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that European clinical research demonstrated that the active ingredient in Serenity, the newest product from its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”), is equally effective as a prescription-only benzodiazepine in treating the symptoms of anxiety.

Key Points: 
  • This research was particularly noteworthy because benzodiazepines, while widely prescribed for anxiety, carry substantial risk of dependency and of seizures in case of withdrawal2.
  • “It was this understanding that drove us to accelerate the launch of Serenity.
  • With Lifeist's expertise with fragrant and flavorful botanicals, Serenity is poised to become the best tasting lavender oil extract supplement on the market.
  • Plus, Serenity ships with a full 30-day supply in every bottle, as compared to the typical 7- or 14-day supply sold in competing lavender-based products.

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Retrieved on: 
Monday, March 6, 2023

“Along these lines, we are excited to announce the updated clinical strategy for GRX-917.

Key Points: 
  • “Along these lines, we are excited to announce the updated clinical strategy for GRX-917.
  • Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.
  • The clinical development plan has been updated to now proceed with a phase 2 study in patients.
  • As part of a strategic review of its pipeline and to enhance operational efficiency and focus, the Company has reduced its workforce by approximately 30%.

Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

Retrieved on: 
Monday, January 9, 2023

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present tomorrow, Tuesday, January 10 at 8:15 a.m. PT/11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference. During the presentation, Cerevel chairperson and chief executive officer, Dr. Tony Coles, will review the Company’s lead programs and upcoming milestones. A question-and-answer session will follow the presentation.

Key Points: 
  • ET at the 41st Annual J.P. Morgan Healthcare Conference.
  • During the presentation, Cerevel chairperson and chief executive officer, Dr. Tony Coles, will review the Company’s lead programs and upcoming milestones.
  • To support a potential registrational package for emraclidine in schizophrenia, Cerevel is prioritizing the completion of nonclinical and clinical pharmacology studies.
  • The live webcast and accompanying slides can be accessed on the Investor Relations section of the Cerevel Therapeutics website here .

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Retrieved on: 
Monday, January 9, 2023

GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.

Key Points: 
  • GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.
  • Initiation of a GRX-917 efficacy study is anticipated in H1 2023 with results expected in 2024.
  • NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.
  • The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, and pharmacokinetic profile of single and multiple ascending doses of orally administered GRX-917.

Datadog Announces PCI Compliance for Log Management and APM

Retrieved on: 
Wednesday, October 19, 2022

NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Datadog, Inc. (NASDAQ: DDOG), the monitoring and security platform for cloud applications, today announced that it has achieved PCI (Payment Card Industry) compliance for its Log Management and Application Performance Management (APM) products.

Key Points: 
  • NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Datadog , Inc. (NASDAQ: DDOG),the monitoring and security platform for cloud applications, today announced that it has achieved PCI (Payment Card Industry) compliance for its Log Management and Application Performance Management (APM) products.
  • By achieving PCI compliance, businesses can now fully leverage Datadog's Log Management and APM products in the parts of their applications requiring compliance to process and store payment and transaction data.
  • "Achieving PCI compliance enables us to work with more organizations and deliver increased value to them," said Emilio Escobar, CISO at Datadog.
  • Learn more about Datadog's Log Management and APM products and Securit y policies.

GABA Therapeutics Appoints Mario David Saltarelli M.D., Ph.D. as CEO and CMO

Retrieved on: 
Thursday, April 7, 2022

NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (GABA) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (atai) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer (CEO) and Chief Medical Officer (CMO) effective April 4, 2022.

Key Points: 
  • NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (GABA) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (atai) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer (CEO) and Chief Medical Officer (CMO) effective April 4, 2022.
  • GABA Therapeutics, an atai Life Sciences platform company, is a clinical stage biotechnology company focused on addressing the growing, unmet medical need in serious psychiatric and neurological disorders, including depression, anxiety, epilepsy, and essential tremor.
  • This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
  • All references in these Forward-Looking Statements to we, and our, refer to GABA and atai, as applicable.

Global Epilepsy Pipeline Landscape Report 2021: Comprehensive Insights for 70+ Companies and 70+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021

This Epilepsy - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Key Points: 
  • This Epilepsy - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Epilepsy R&D.
  • The therapies under development are focused on novel approaches to treat/improve Epilepsy.
  • This segment of the Epilepsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.